Fiscal Period | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
Net Income/ Starting Line | 0.63 | 1.25 | 2.25 | 4.29 |
Depreciation/ Depletion | 1.56 | 1.63 | 1.76 | 1.37 |
Non- Cash Items | 1.86 | 1.63 | 1.40 | 1.24 |
Changesin Working Capital | -3.25 | -2.84 | -4.64 | -5.28 |
Cashfrom Operating Activities | 0.79 | 1.66 | 0.77 | 1.62 |
Capital Expenditures | -1.02 | -0.86 | 0.00 | -3.67 |
Other Investing Cash Flow Items Total | 0.01 | -1.41 | 0.01 | 0.01 |
Cashfrom Investing Activities | -1.01 | -2.27 | 0.01 | -3.67 |
Financing Cash Flow Items | -0.86 | -1.07 | -1.78 | -1.33 |
Issuance( Retirement)of Stock Net | 0.68 | 1.89 | - | 0.00 |
Issuance( Retirement)of Debt Net | 0.46 | -0.19 | 3.46 | 3.41 |
Cashfrom Financing Activities | 0.28 | 0.62 | 1.68 | 2.07 |
Net Changein Cash | 0.07 | 0.02 | 2.47 | 0.02 |
Cash Interest Paid | 1.87 | 1.64 | 1.41 | 1.25 |
Cash Taxes Paid | 0.22 | 0.38 | 0.67 | 0.47 |
Concord Drugs Dividend Concord Drugs Bonus Concord Drugs News Concord Drugs AGM Concord Drugs Rights Concord Drugs Splits Concord Drugs Board Meetings Concord Drugs Key Metrics Concord Drugs Shareholdings Concord Drugs Profit Loss Concord Drugs Balance Sheet Concord Drugs Q1 Results Concord Drugs Q2 Results Concord Drugs Q3 Results Concord Drugs Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks